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Abstract 
 Here we present the first report of solitary primary peripheral nerve onset 
cytotoxic molecule (CM)-positive peripheral T-cell lymphoma (PTCL) diagnosed after 
nerve biopsy. An 84-year-old female with rheumatoid arthritis (RA) complained of 
asymmetric severe tenderness in her upper limbs. The biopsy pathology revealed a 
direct invasion of CM-positive PTCL. When RA patients complain of numbness, 
tenderness or weakness, lymphomatic peripheral nerve invasion should be considered. 
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Introduction 
 Although the primary lesion of malignant lymphoma (ML) are usually 
restricted to the lymph node, the onset of some ML are extranodal1). Very few cases of 
the onset of ML are linked to the peripheral nerve, and most are of the B-cell type2). 
Thus, solitary primary peripheral nerve onset T-cell lymphoma is extremely rare. The 
subject in the present case developed a chronic progressive sensorimotor disturbance in 
the left upper limb during treatment of rheumatoid arthritis (RA). Left median nerve 
biopsy pathology proved that the patient was suffering from solitary peripheral nerve 
onset cytotoxic molecule (CM)-positive peripheral T-cell lymphoma (PTCL). 
 
Case report 
The patient is a female diagnosed as seronegative rheumatoid arthritis (RA) 
on the basis of tenderness and morning stiffness in her finger joints at the age of 77 and 
treated with MTX for 5 years. When she reached 82 year-old, she complained of 
numbness in her left thumb, index and middle fingers. Iguratimod (25 mg/day, NF-κΒ 
inhibitor) was added because the exacerbation of RA was suspected. 
In spite of the treatment, the numbness in her fingers persisted for 6 M, and 
subcutaneous injection of golimumab (50 mg/M, anti-tumor necrosis factor (TNF-α) 
monoclonal antibody) replaced MTX. However, her numbness in her fingers gradually 
spread over her left forearm over the next 7 M. Although the dose of golimumab was 
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increased to 100 mg/M, her left arm showed progressive tenderness and weakness for 
an additional 2 M. She was thus admitted to our hospital at the age of 84, 6 years and 2 
months after the diagnosis of RA (Fig. 1A). 
Upon neurological examination, her left arm showed distal dominant 
moderate weakness with superficial muscle atrophy. Her soft touch sense and pain sense 
were decreased in left median nerve area distal dominantly with severe tenderness. Both 
Phalen test and Tinel sign were negative. On the other hand, her lower limbs showed no 
obvious weakness nor sensory disturbance. However, her vibration sense was also 
impaired in not only her left wrist joint (10 seconds in right, 0 second in left), but also in 
her bilateral distal lower limbs (2 seconds in both medial malleolus). Laboratory data 
revealed a normal WBC count, erythrocyte sedimentation rate and C-reaction protein 
and a slightly elevated level of soluble interleukin-2 receptor (502 IU/mL; normal 
122-496 IU/mL). Anti-N-acetylglucosamine (GalNAc)-GD1a IgG antibody assessed by 
enzyme-linked immunosorbent assay (ELISA) was positive, while rheumatoid factor, 
anti-cyclic citrullinated peptid antibody (CCP) antibody, onconeural antibodies 
(targeting AMPH, CV2, PNMA2, Ri, Yo, Hu, recoverin, SOX1, titin, zic4, GAD65 and 
Tr) and antinuclear antibody were negative. Serum Epstein-Barr virus DNA assessed by 
polymerase chain reaction (PCR) was negative. Cerebrospinal fluid (CSF) examination 
revealed normal cell number (mono 1/mm3), cytology and glucose with a slightly high 
protein level (49 mg/dl). A nerve conduction study (NCS) revealed a demyelinating 
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change in the left median and radial motor nerves, i.e., prolonged distal latency, 
temporal dispersion, conduction block and reduced velocity. The frequency of the 
F-wave action potential decreased. The left median nerve showed no evoked sensory 
nerve action potential (SNAP), and the left ulnar nerve had a low amplitude (Table 1). 
As the whole body computed tomography (CT), magnetic resonance imaging 
of whole spine, gastroscopy and colonoscopy did not reveal any finding of malignancy, 
spinal canal stenosis nor inflammation, 18F-Positron emission tomography (18F-PET) 
/CT was conducted for further investigation. It showed abnormal uptake in left cervical 
roots and in the brachial nerve plexus (Fig. 1B and Fig. 1C, filled arrows), which 
indicated solitary primary peripheral nerve malignant neoplasm such as lymphoma. In 
case of malignant neoplasm, it would be fatal without appropriate treatment, So, we 
decided to conduct the median nerve biopsy. The biopsy specimen of the left median 
nerve (Fig. 1D) showed extensive infiltration of atypical lymphoid cells (Fig. 1E 
triangles, Fig. 1F and Fig. 1G), and peripheral nerve bundles disappearance. The 
number of large myelinated fibers was extremely low (3,600/mm3) with frequent 
degenerated fibers (Fig. 1E, arrows). The lymphoid cells were positive for CD3 (Fig. 
1H), CD8 (Fig. 1I) and T-cell intracytoplasmic antigen-1 (Fig. 1J), but negative for 




Based on the above data, the patient was diagnosed as having solitary primary 
CM-positive PTCL. After treatment with methotrexate and then forodesine 
hydrochloride, her weakness and sensations gradually improved as 18F-PET/CT uptake 
vanished (Fig. 1M and 1N, open arrows). Six month after hospital transfer for 
rehabilitation, she deceased because of recurrence of her original PTCL. 
 
Discussion 
ML usually involves the lymph node, but onset in around 30% of cases is 
extranodal1). Only 0.7% of such extranodal ML are onset by the peripheral nerve, and 
most of them are of the B-cell type2). Only three cases of peripheral nerve onset T-cell 
lymphoma have been reported thus far: NK/T-cell lymphoma3), an unclassifiable T cell 
lymphoma, and an adult T cell leukaemia/lymphoma4). The present case is the first 
report of primary peripheral nerve onset CM-positive PTCL. 
Peripheral neuropathies in ML are caused by direct invasion 
(neurolymphomatosis), paraneoplastic neuropathy, drug or radiation-induced 
neuropathy and infection5). Although there are several anti-glycolipid antibodies found 
in lymphoma associated neuropathy patients, the pathogenesis remains improbable6). 
Furthermore, the present case with sensory dominant neuropathy is positive for IgG 
anti-GalNAc-GD1a antibody, which is exclusively found in patients with pure motor 
variant Guillain-Barre Syndrome7). So, the pathogenesis of the antibody in this patient is 
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unclear. Even though the present case showed distal dominant sensory disturbance 
which could not be explained with the lesion in spinal cord nor nerve root and a 
demyelinating pattern in NCS, as is frequently observed in paraneoplastic neuropathy4), 
her asymmetric severe tenderness also suggested direct invasion2), which was proven by 
biopsy pathology (Fig. 1D, Fig. 1E, Fig. 1F, Fig. 1G, Fig. 1H, Fig. 1I, Fig. 1J, Fig. 1K 
and Fig. 1L). 
MTX is sometimes associated with lymphoproliferative diseases8). However, 
the present case emerged 7 M after MTX (6mg/week, oral administration) withdrawal 
and exacerbated after golimumab induction. Furthermore, her symptoms improved 
temporarily after treatment for her lymphoma with MTX (1,300mg, intravenous 
administration). Thus, MTX discontinuation or golimumab induction seemed more 
involved in the pathogenesis of the present case9)10)11). 
 To the best of our knowledge, this is the first report of primary peripheral 
nerve onset CM-positive PTCL. When RA patients treated with not only MTX but also 
iguratimod and golimumab complain of numbness, tenderness or weakness, 
lymphomatic peripheral nerve invasion should be considered. 
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Figure legends 1 
(A) The patient’s clinical course from the diagnosis of her rheumatoid arthritis 2 
to the admission to our hospital. M, months; Y, years. (B and C) The patient’s 3 
18F-PET/CT on admission, showing abnormal uptake (filled arrows) in left cervical 4 
roots and brachial nerve plexus. (D) Site of the left median nerve biopsy (an arrow). (E) 5 
Toluidine blue staining of the biopsy specimen showing extensive infiltration of 6 
atypical lymphoid cells (filled arrows), and (F) magnification showing frequent 7 
degenerated fibers and disappearance of peripheral nerve bundles. (G) 8 
Hematoxylin-eosin staining showing extensive infiltration of atypical lymphoid cells 9 
and disappearance of peripheral nerve bundles. Immunostaining of the biopsy specimen 10 
was positive for (H) CD3, (I) CD8 and (J) T-cell intracytoplasmic antigen-1 (TIA-1), 11 
but negative for (K) CD56 with (L) an elevated Ki67 index in these lymphoid cells. (M 12 
and N) After treatment, 18F-PET/CT showed the disappearance of abnormal uptake in 13 
left cervical roots and the brachial nerve plexus (open arrows).  14 
